Aleš Obr
About
Aleš Obr is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Aleš Obr has authored 21 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 13 papers in Oncology and 12 papers in Genetics. Recurrent topics in Aleš Obr's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (11 papers) and CAR-T cell therapy research (8 papers). Aleš Obr is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (11 papers) and CAR-T cell therapy research (8 papers). Aleš Obr collaborates with scholars based in Czechia, United Kingdom and Belgium. Aleš Obr's co-authors include Wojciech Jurczak, Kami J. Maddocks, Johannes Weirather, Eva González‐Barca, Gianluca Gaïdano, Johannes Duell, Maren Dirnberger‐Hertweck, Gilles Salles, Sumeet Ambarkhane and Zsolt Nagy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.
In The Last Decade
Aleš Obr
20 papers receiving 476 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Aleš Obr Czechia | 8 | 384 | 366 | 125 | 80 | 74 | 21 | 483 | ||
| Yajuan Qin United States | 5 | 398 1.0× | 289 0.8× | 85 0.7× | 120 1.5× | 72 1.0× | 8 | 448 | ||
| Brian Hess United States | 11 | 452 1.2× | 354 1.0× | 96 0.8× | 115 1.4× | 122 1.6× | 53 | 597 | ||
| David Lewis United Kingdom | 12 | 388 1.0× | 354 1.0× | 138 1.1× | 103 1.3× | 120 1.6× | 39 | 546 | ||
| Huang Huang Canada | 8 | 343 0.9× | 245 0.7× | 69 0.6× | 126 1.6× | 93 1.3× | 14 | 413 | ||
| Martin Dreyling Germany | 13 | 344 0.9× | 470 1.3× | 226 1.8× | 66 0.8× | 84 1.1× | 28 | 622 | ||
| Pratyush Giri Australia | 9 | 337 0.9× | 253 0.7× | 93 0.7× | 140 1.8× | 142 1.9× | 29 | 451 | ||
| Nicole Adrian Germany | 8 | 323 0.8× | 192 0.5× | 66 0.5× | 111 1.4× | 131 1.8× | 10 | 428 | ||
| Marie-Elisabeth Goebeler Germany | 6 | 324 0.8× | 197 0.5× | 67 0.5× | 100 1.3× | 110 1.5× | 7 | 392 | ||
| Taoufik El Gnaoui France | 7 | 226 0.6× | 341 0.9× | 120 1.0× | 48 0.6× | 40 0.5× | 17 | 388 | ||
| Vaishalee P. Kenkre United States | 13 | 260 0.7× | 258 0.7× | 208 1.7× | 26 0.3× | 120 1.6× | 37 | 456 |
Countries citing papers authored by Aleš Obr
Since
Specialization
Citations
This map shows the geographic impact of Aleš Obr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleš Obr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleš Obr more than expected).
Fields of papers citing papers by Aleš Obr
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Aleš Obr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleš Obr. The network helps show where Aleš Obr may publish in the future.
Co-authorship network of co-authors of Aleš Obr
This figure shows the co-authorship network connecting the top 25 collaborators of Aleš Obr. A scholar is included among the top collaborators of Aleš Obr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleš Obr. Aleš Obr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Belada, David, Heidi Móciková, Aleš Obr, et al.. (2025). 647 | SAFETY AND EFFICACY OF GLOFITAMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA ‐DATA FROM REAL‐WORLD STUDY. Hematological Oncology. 43(S3).
2.
Obr, Aleš, Andrea Janíková, Heidi Móciková, et al.. (2022). Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. Annals of Hematology. 102(1). 107–115.
3.
Janíková, Andrea, Vít Procházka, David Belada, et al.. (2022). Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world. European Journal Of Haematology. 109(2). 162–165.
4.
Čerňan, Martin, Tomáš Szotkowski, Aleš Obr, et al.. (2021). COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic. Clinical Lymphoma Myeloma & Leukemia. 21(9). 606–612.
5.
Maddocks, Kami J., Eva González‐Barca, Wojciech Jurczak, et al.. (2021). Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology. 39(15_suppl). 7513–7513.
6.
Vodička, Pavel, Andrea Janíková, Vít Procházka, et al.. (2021). POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLD. Hematological Oncology. 39(S2).
7.
Obr, Aleš, Pavel Klener, Andrea Janíková, et al.. (2021). Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group. Blood. 138(Supplement 1). 4526–4526.
8.
Salles, Gilles, Johannes Duell, Eva González‐Barca, et al.. (2020). Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet Oncology. 21(7). 978–988.
9.
Procházka, Vít, et al.. (2020). Current perspective on diagnosis and treatment of primary central nervous system lymphomas. 14(3). 110–113.
10.
Salles, Gilles, Johannes Duell, Eva González‐Barca, et al.. (2020). ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 20. S267–S268.
11.
Maddocks, Kami J., Johannes Duell, Eva González‐Barca, et al.. (2020). Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 19–21.
12.
Kolstad, Arne, Tim Illidge, Nils Bolstad, et al.. (2020). Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances. 4(17). 4091–4101.
13.
Duell, Johannes, Kami J. Maddocks, Eva González‐Barca, et al.. (2019). Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 1582–1582.
14.
Maddocks, Kami J., Johannes Duell, Eva González‐Barca, et al.. (2019). Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.. Journal of Clinical Oncology. 37(15_suppl). 7521–7521.
15.
Salles, Gilles, Johannes Duell, Eva González‐Barca, et al.. (2019). PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND). Hematological Oncology. 37(S2). 173–174.
16.
Obr, Aleš, Pavel Klener, Eva Kriegová, et al.. (2019). High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma. Blood. 134(Supplement_1). 3995–3995.
17.
Obr, Aleš, et al.. (2018). TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(11). 762–768.
18.
Obr, Aleš, Vít Procházka, Tomáš Papajík, et al.. (2018). Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry†. Leukemia & lymphoma. 60(3). 748–755.
19.
Salles, Gilles, Johannes Duell, Eva González‐Barca, et al.. (2018). Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind. Blood. 132(Supplement 1). 227–227.
20.
Obr, Aleš, Pavel Klener, David Belada, et al.. (2017). MAINTENANCE RITUXIMAB IMPROVES SURVIVAL IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP. Hematological Oncology. 35(S2). 205–206.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yajuan Qin Breakdown of academic impact, for papers by Brian Hess Breakdown of academic impact, for papers by David Lewis Breakdown of academic impact, for papers by Huang Huang Breakdown of academic impact, for papers by Martin Dreyling Breakdown of academic impact, for papers by Pratyush Giri Breakdown of academic impact, for papers by Nicole Adrian Breakdown of academic impact, for papers by Marie-Elisabeth Goebeler Breakdown of academic impact, for papers by Taoufik El Gnaoui Breakdown of academic impact, for papers by Vaishalee P. Kenkre